13F Holdings
中文EN

JAGX Jaguar Health, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1585608 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY129.7%
TTM net income YoY18.7%
TTM EPS YoY199.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin81.5%
Operating margin-91.2%
Net margin-121.0%
FCF margin—
EBITDA margin-84.2%

Returns

ROE-252.4%
ROA-79.9%
ROIC (approx.)-230.8%
Asset turnover0.66x

Leverage & solvency

Liabilities / assets42.7%
Debt / equity0.00x
Current ratio1.28x
Interest coverage-21.50x

Cash quality & payout

Operating cash flow / net income0.21x
Accruals ratio-63.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$11.51M$11.69M$9.76M$11.96M$4.33M
Cost of revenue$3.77M$1.96M$2.04M$2.02M$2.33M
Gross profit$7.74M$9.73M$7.72M$9.94M$2.00M
R&D expense$24.97M$16.54M$18.60M$17.65M$15.08M
SG&A expense$18.64M$16.33M$16.59M$17.87M$17.10M
Operating income-$45.91M-$30.83M-$34.29M-$34.41M-$40.71M
Interest expense$67,000$231,000$6.38M$12.72M$8.42M
Pretax income-$54.00M-$39.25M-$41.90M-$48.40M-$52.60M
Income tax$0$0$0$0$0
Net income-$53.58M-$38.49M-$41,900-$48,400-$52,600
EBITDA-$43.99M-$28.93M-$32.28M-$32.43M-$38.99M
EPS (basic)-22.97-130.69-2,678.17-36.18-88.22
EPS (diluted)-22.97-130.69-2,678.17-36.18-88.22
Weighted avg. shares (diluted)2.33M294,53415,4211.31M596,154
Balance sheet
Cash & equivalents$968,000$8.00M$6.47M$5.47M$17.05M
Receivables$1.52M$1.53M$1.97M$1.88M$1.71M
Inventory$8.60M$10.35M$9.19M$7.02M$4.90M
Current assets$20.34M$32.20M$27.96M$22.32M$28.43M
PP&E, net$463,000$464,000$496,000$557,000$650,000
Intangibles$16.02M$18.48M$20.12M$22.44M$22.65M
Total assets$38.32M$53.42M$50.76M$47.45M$53.27M
Current liabilities$40.65M$19.70M$13.99M$30.34M$15.47M
Total liabilities$57.01M$44.45M$45.87M$48.81M$41.41M
Shareholders' equity-$17.29M$7.29M$4.96M-$660,000$11.61M
Cash flow statement
Operating cash flow-$23.69M-$29.38M-$33.24M-$33.10M-$34.97M
Capital expenditure—$16,000—$77,000$6,000
Free cash flow—-$29.40M—-$33.18M-$34.98M
Investing cash flow-$41,000-$231,000—-$1.68M-$6,000
Financing cash flow$23.67M$31.20M$34.23M$23.18M$43.94M
Depreciation & amortization$1.91M$1.90M$2.01M$1.98M$1.72M
Stock-based compensation$831,000$1.64M$2.11M$3.32M$3.97M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.